SCHEMBL6705012

SCHEMBL6705012

C=CC(CCBr)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.36
HRH1 P35367 2/20 0.35
TAAR1 Q96RJ0 3/20 0.34
RIPK1 Q13546 2/20 0.34
HTR2A P28223 2/20 0.33
CYP3A4 P08684 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
SMPD1 P17405 1/20 0.33
DRD1 P21728 1/20 0.33
TBXA2R P21731 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15393365 0.83 CYP2C19 (0.38) CYP2C19HRH1TAAR1HTR2ACYP3A4
SCHEMBL8014725 0.82 POLB (0.41) CYP2C19HRH1TAAR1RIPK1HTR2A
SCHEMBL3804767 0.81 CYP2C19 (0.37) CYP2C19HRH1TAAR1RIPK1HTR2A
SCHEMBL28644783 0.79 HRH1 (0.56) CYP2C19HRH1TAAR1HTR2ACYP3A4
SCHEMBL6016113 0.79 CYP2C19 (0.36) CYP2C19HRH1TAAR1RIPK1HTR2A
SCHEMBL5560718 0.79 TRPA1 (0.44) CYP2C19HRH1RIPK1SMN1; SMN2TDP1
SCHEMBL3022300 0.79 AOC3 (0.42) CYP2C19HRH1TAAR1RIPK1HTR2A
SCHEMBL8465661 0.78 ACP3 (0.44) CYP3A4SMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL5561239 0.78 CYP2C19 (0.35) CYP2C19HRH1RIPK1HTR2ACYP3A4
SCHEMBL3785691 0.76 TRPA1 (0.38) CYP2C19HRH1RIPK1HTR2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 CYP2C19 714/4885HRH1 468/4885TAAR1 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.